Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02460133
Other study ID # SAIL-001
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date July 2015
Est. completion date October 2023

Study information

Verified date February 2023
Source Nova Scotia Health Authority
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot study is crucial to determining whether treating individuals who are at high risk for transmission or re-infection will impact HCV reinfection rates. It will establish the feasibility of DAA treatment in corrections facilities, as well as delineate the underlying immune basis of HCV cure and reinfection.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 44
Est. completion date October 2023
Est. primary completion date October 2023
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - An offender at the PEI Provincial Correction Centre during the enrollment time - Male, 18 -70 years of age, inclusive, at time of screening - Chronic HCV genotype 1 infection - HCV infection, as demonstrated by positive HCV immunosorbant assay and detectable HCV viral load - No evidence of decompensated liver disease (refractory ascites, variceal bleed within 1 year, active hepatic encephalopathy or Child-Pugh score greater than 6) - HIV negative - Males must be abstinent from sexual intercourse, surgically sterile or agree to practice two effective forms of birth control from those listed below, throughout the course of the study, starting with Study Day 1 and for 7 months after the last dose of study drug (or per local RBV label): - Partner(s) using an IUD (intrauterine device), - Partner(s) using oral, injected, or implanted methods of hormonal contraceptives, - Subject and/or partner(s) using condoms, contraceptive sponge, or diaphragm with spermicidal jellies or creams. - Subjects must be able to understand and adhere to the study visit schedule and all other protocol requirements - Must voluntarily sign and date an informed consent form, approved by a Research Ethics Board prior to the initiation of any screening or study specific procedures Exclusion Criteria: - History of severe, life-threatening or other significant sensitivity to any drug - Positive test result at screening for Hepatitis B surface antigen - Prior therapy with direct acting antivirals for the treatment of HCV - Evidence of decompensated liver disease (current or past refractory ascites, variceal bleed within 1 year, active hepatic encephalopathy) - HIV positive screening test - Unwilling to follow up for 48 weeks after treatment completion - Use of any herbal supplements (including milk thistle) within 2 weeks or 10 half-lives of the respective supplement, whichever is longer, prior to the first dose of study drug - HCV genotype performed during screening indicating unable to genotype or co-infection with any other HCV genotype - Use of any medications contraindicated for use with the study regimen - Clinically significant abnormalities, other than HCV-infection, based upon the results of a medical history, physical examination, vital signs, and laboratory profile that make the subject an unsuitable candidate for this study in the opinion of the investigator - Serum Alpha-Fetoprotein (AFP) > 200 ng/mL at screening - Any cause of liver disease other than chronic HCV-infection, including but not limited to the following: - Hemochromatosis - Alpha-1 antitrypsin deficiency - Wilson's disease - Autoimmune hepatitis - Alcoholic liver disease - Nonalcoholic steatohepatitis - Drug-related liver disease - Screening laboratory analyses showing any of the following abnormal laboratory results: - ALT > 5 × upper limit of normal (ULN) - Aspartate aminotransferase (AST) > 5 × ULN - Calculated creatinine clearance (using Cockcroft-Gault method) < 60 mL/min - Albumin 25 g/L - Prothrombin time/International normalized ratio (INR) > 2.3. - Hemoglobin < LLN - Platelets < 60,000 cells per mm3 - Absolute neutrophil count (ANC) < 1500 cells/µL - Total bilirubin = 51 umol/L - History of solid organ transplantation. - Receipt of any investigational product within a time period equal to 10 half-lives of the product, if known, or a minimum of 6 weeks prior to study drug administration. - Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive paritaprevir, dasabuvir, ombitasvir, ritonavir and/or RBV. - Current enrollment in another clinical study, prior enrollment in this study, or previous exposure to paritaprevir, ombitasvir, or dasabuvir. Concurrent participation in a non-interventional, epidemiologic or registry trials may be permitted with approval of the principal investigator. - The use of colony stimulating factors, such as granulocyte colony stimulating factor (GCSF) or erythropoietin within 2 months of the screening period. - Uncontrolled clinically significant cardiac, respiratory (except mild asthma), hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness, which is unrelated to the hepatic disease.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Paritaprevir

Ritonavir

Dasabuvir

Ombitasvir

Ribavirin
In genotype 1b individuals without cirrhosis, treatment will NOT include ribavirin.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Lisa Barrett PEI Provincial Correction Centre

Outcome

Type Measure Description Time frame Safety issue
Primary Re-infection rate in individuals treated with DAA therapy This will require HCV quasispecies determination at baseline and in potentially re-infected individuals. Re-infection will require demonstration of HCV RNA above level of detection after SVR12 with a phyogenetically distinct HCV species. 1 year following treatment.
Secondary Percentage of subjects with sustained virologic response at 12 weeks post treatment 12 Weeks post treatment
Secondary Change in fibrosis measured by transient elastography From day 0 to the end of follow-up
Secondary Global and HCV-specific T cell function before and after treatment with DAA therapy. From day 0 to end of follow-up
Secondary Global and HCV-specific B cell function before and after treatment with DAA therapy. From day 0 to end of follow-up
Secondary Global and HCV-specific NK cell function before and after treatment with DAA therapy. From day 0 to end of follow-up
See also
  Status Clinical Trial Phase
Completed NCT02907996 - Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea
Completed NCT02207088 - Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease Phase 3
Not yet recruiting NCT02893046 - HCV Care Pathway in Ile-de-France N/A
Completed NCT01428063 - Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials Phase 2
Completed NCT01396005 - A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123) Phase 1
Completed NCT01195181 - Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice. Phase 4
Completed NCT00219999 - Hepatitis C Virus and the Humoral Immune System N/A
Completed NCT02243293 - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection Phase 2/Phase 3
Completed NCT02265237 - A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1) Phase 3
Not yet recruiting NCT06104046 - Prevalence of Seroconversion of Hepatitis c Virus Among Children With CKD on Regular Hemodialysis
Completed NCT02604017 - A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection Phase 3
Withdrawn NCT00947245 - Japanese Bridging Study Conducted in the United States Phase 1
Completed NCT01713283 - Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection Phase 2
Completed NCT01479881 - A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus Phase 1
Completed NCT01458535 - A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-267 and With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV) Phase 2
Completed NCT01193361 - Ph IIA Study (SOC +/- NS5B) Phase 2
Completed NCT01241773 - TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir Phase 1
Completed NCT01006031 - Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4 Phase 2/Phase 3
Completed NCT00819026 - Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors N/A
Completed NCT00382798 - Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin Phase 1/Phase 2